Congress Can Keep Medical Cannabis Patients at the Center of Federal Policy
For three decades, medical cannabis patients, healthcare professionals, researchers, and state governments have worked to establish regulated medical cannabis programs and build the clinical experience and scientific evidence necessary for federal recognition of cannabis as medicine. Congress supported this progress by protecting state programs from federal interference and removing longstanding barriers to research. Together, these efforts laid the foundation for a historic shift in federal medical cannabis policy.
In April 2026, Attorney General Order No. 6754-2026 placed qualifying medical cannabis products in Schedule III and established a federal registration pathway for state medical cannabis businesses. This was a major breakthrough, but federal recognition has not ended discrimination against patients or established a national medical cannabis program. Outdated federal policies continue to create barriers to healthcare, housing, employment, veterans' services, and other essential benefits and protections.
Congress must address these discriminatory policies rather than leave patients to fight for their rights individually through the courts. The FY2027 appropriations process provides an immediate opportunity to protect patients, direct federal agencies to update outdated policies, strengthen product safety and research, and prepare for the integration of cannabis-based medicines into American healthcare.
Americans for Safe Access (ASA) has developed specific recommendations for seven congressional appropriations subcommittees. These proposals focus on addressing the gaps left by the Attorney General's order while protecting patients during the transition to federal medical cannabis regulation.
FY2027 Appropriations & Medical Cannabis Patients
Congress has a long history of influencing medical cannabis policy through appropriations. Since 2014, the longstanding Medical Cannabis Amendment in the Commerce, Justice, Science, and Related Agencies (CJS) appropriations bill has restricted Department of Justice (DOJ) interference with state medical cannabis programs, helping patients and states establish regulated systems despite federal prohibition.
Now that federal recognition is beginning, Congress faces a different challenge. The Attorney General's order created a federal registration pathway, but it did not establish the healthcare policies, patient protections, or coordinated medical supply chains necessary for a functioning national medical cannabis system.
Congress can use appropriations legislation, funding directives, committee report language, and oversight to require federal agencies to address these gaps within their authority. These actions cannot replace comprehensive medical cannabis legislation, but they can help ensure that patients are protected while Congress develops a national framework.
With the current continuing resolution scheduled to expire on December 11, 2026, Congress has a limited window to incorporate these priorities into FY2027 funding legislation.
Patient Priorities: ASA's Requests Across Seven Appropriations Subcommittees
ASA is urging Congress to take coordinated action across seven federal funding bills. Each addresses a different part of the federal system that affects medical cannabis patients, from access to medicine and healthcare to housing, employment, veterans' services, and product safety.
Commerce, Justice, Science, and Related Agencies
The most immediate priority is protecting patient access as DOJ and the Drug Enforcement Administration (DEA) implement the Attorney General's order. Congress should retain the longstanding Medical Cannabis Amendment, reject anti-rescheduling and additional punitive provisions, and require equitable, transparent DEA registration decisions with appropriate reporting and oversight.
Congress should also direct DOJ and DEA to work with states and territories facing barriers to establishing federally compliant medical cannabis supply chains. Reasonable corrective-action periods, targeted registration opportunities, and a patient-access continuity plan can help prevent unnecessary disruptions while maintaining federal safety and diversion controls.
ASA is also calling for DOJ guidance addressing applicable protections under the Americans with Disabilities Act, Fair Housing Act, and Section 504 of the Rehabilitation Act, emphasizing individualized assessments rather than categorical exclusions based solely on participation in state medical cannabis programs.
Read ASA's detailed Commerce, Justice, Science appropriations recommendations.
Labor, Health and Human Services, Education, and Related Agencies
Medical cannabis patients continue to encounter barriers in hospitals, hospices, nursing homes, assisted living facilities, federally qualified health centers, transplant programs, and other healthcare settings. ASA is asking Congress to direct the Department of Health and Human Services (HHS) and Centers for Medicare & Medicaid Services (CMS) to issue guidance addressing categorical denial of care and medical cannabis documentation.
These recommendations also include standardized medical cannabis data fields, studies examining insurance coverage and healthcare costs, and the establishment of an HHS Office of Medical Cannabis and Cannabinoid Control to coordinate federal oversight and healthcare integration.
Read ASA's detailed Labor, Health and Human Services appropriations recommendations.
Transportation, Housing and Urban Development, and Related Agencies
Patients should not face eviction, denial of admission, termination of housing assistance, or refusal of reasonable accommodation solely because they participate in state-authorized medical cannabis programs. Yet outdated federal housing policies continue to expose patients to these risks.
ASA is urging Congress to direct the Department of Housing and Urban Development (HUD) to withdraw and replace outdated guidance and clarify patient protections, consistent with applicable federal law. Updated policies should address housing decisions through individualized review rather than blanket exclusions.
Read ASA's detailed Transportation, Housing and Urban Development appropriations recommendations.
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies
Patients need consistent product-safety standards, accurate labeling, reliable testing, and access to information about the medicines they consume. ASA is calling for Food and Drug Administration (FDA) oversight addressing medical cannabis testing and product safety, hemp-derived cannabinoid labeling, adverse-event reporting, and real-world evidence.
Recent changes to federal hemp law make these recommendations especially urgent. Patients who relied on hemp-derived therapeutic products may face new access barriers, and Congress should require federal agencies to assess the consequences of these changes while developing appropriate safety standards and medical access policies.
Read ASA's detailed Agriculture and FDA appropriations recommendations.
Military Construction, Veterans Affairs, and Related Agencies
Veterans should be able to discuss medical cannabis with their healthcare providers without encountering unnecessary barriers to care. ASA is urging Congress to direct the Department of Veterans Affairs (VA) to replace outdated VHA Directive 1315 and allow clinicians to discuss cannabis-based medicines, make state-law-permitted recommendations and referrals, complete state medical cannabis forms, and document treatment in medical records.
Congress should also require VA to report on veterans' access to medical cannabis, opportunities for integrating cannabis-based medicines into care, and potential healthcare costs and savings.
Read ASA's detailed Military Construction and Veterans Affairs appropriations recommendations.
Financial Services and General Government
A positive cannabis drug test does not, by itself, establish impairment, misconduct, or an employee's ability to perform a job safely. Nevertheless, federal workplace policies can treat the presence of cannabis metabolites as grounds for adverse employment decisions without evidence of actual impairment.
ASA is asking Congress to require the Office of Personnel Management (OPM), working with HHS, the Substance Abuse and Mental Health Services Administration (SAMHSA), and DOJ, to review and update federal workplace policies. Guidance should distinguish cannabis detection from impairment and require individualized, job-related assessments while preserving appropriate safety-sensitive restrictions.
Read ASA's detailed Financial Services and General Government appropriations recommendations.
Department of Defense
Military personnel face distinct challenges involving medical cannabis, CBD, hemp-derived cannabinoids, healthcare disclosure, and continuity of care. ASA is calling on Congress to direct the Department of Defense to review these policies and establish appropriate clinical-review procedures.
Updated policies should account for military readiness and actual safety risks while addressing disability evaluations, transitions from active duty, and continuity of medical care.
Read ASA's detailed Defense appropriations recommendations.
Senate Appropriations Proposals Create an Opportunity for Action
The Senate Appropriations Committee has now released all twelve of its FY2027 funding proposals, providing Congress with an opportunity to address medical cannabis patient protections across multiple federal agencies.
On November 10, the committee released its Agriculture/FDA and Military Construction/VA proposals. These bills include provisions concerning hemp regulation, cannabinoid research, FDA oversight, and medical marijuana research within VA. However, they do not fully address the patient-access barriers, product-safety standards, and healthcare integration policies ASA is seeking.
On November 12, the committee released its CJS proposal, which retains the longstanding Medical Cannabis Amendment, includes Nebraska, and omits two concerning provisions from the House version: language restricting rescheduling and language expressly preserving enhanced federal drug penalties near schools and other protected locations. ASA is urging congressional negotiators to maintain these protections and ensure the restrictive House provisions are not restored in final legislation.
On November 16, the Senate released its remaining five proposals, including Labor, Health and Human Services; Transportation, Housing and Urban Development; Financial Services and General Government; and Defense. These funding bills provide additional opportunities to address healthcare discrimination, housing protections, federal workplace policies, and medical cannabis issues affecting service members.
While the release of these proposals represents progress, the bills have not been enacted, and the Senate's current drafts do not resolve the full range of patient protections ASA is seeking. Congressional action is still necessary to ensure medical cannabis patients are not left behind as federal policy changes.
Building Toward a National Medical Cannabis Framework
The Attorney General's April 2026 order represents a significant shift in federal policy, but successfully implementing Schedule III registration will not complete the work of medical cannabis reform. Federal recognition does not automatically establish national product standards, insurance coverage, coordinated medical oversight, patient protections, or interstate medical access.
ASA's long-term goal is comprehensive legislation that integrates cannabis-based medicines into the American healthcare system. The proposed Medical Cannabis and Cannabinoid Act (MCCA) would build on decades of state medical cannabis experience to establish consistent standards, meaningful patient protections, coordinated federal oversight, and equitable access to cannabis-based medicines.
State medical cannabis programs provided the experience, evidence, and infrastructure necessary to make federal reform possible, but maintaining separate state systems was never the final goal. Congress now has an opportunity to protect patients during the transition while laying the groundwork for comprehensive legislation in the 120th Congress.
The Window for Congressional Action Is Now
The FY2027 appropriations process is an immediate opportunity to turn federal recognition of medical cannabis into meaningful protections for patients. Congress can preserve the progress already made, direct federal agencies to end discriminatory policies, establish accountability for implementing federal registration requirements, and begin preparing the healthcare system for cannabis-based medicines.
Patients have spent decades advocating for the recognition of cannabis as medicine. They should not have to spend another generation fighting outdated federal policies, navigating inconsistent healthcare rules, or defending their access to medicine through individual court challenges.
Federal recognition of cannabis as medicine must be followed by federal policies that protect the patients who made that recognition possible. Congress has the authority to help make that happen, but lawmakers need to hear directly from patients, caregivers, healthcare professionals, and advocates.
Take Action: Tell Congress to Protect Medical Cannabis Patients
ASA is asking supporters to contact key members of the Senate Appropriations Committee and urge them to include medical cannabis patient protections in FY2027 funding legislation. Our action campaign provides contact information, prepared calling scripts, and specific requests that advocates can share with congressional offices.
TAKE ACTION NOW: Tell the Senate to Protect Medical Cannabis Patients in FY2027 Appropriations
For our complete recommendations, legislative proposals, congressional developments, and supporting resources, visit ASA's FY2027 Medical Cannabis Appropriations Hub.
Share this page